Test Price
2,800 AED✅ Home Collection Available
ADAM17 Gene Inflammatory Skin and Bowel Disease, Neonatal, Type 1 Genetic Test in UAE | 2800 AED | DHA Approved
Executive Summary & Core Metrics
- ✓ 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Processing (Cert: INT/EGQ/2509DA/3139).
- ✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- ✓ Clinical Guidance: Complimentary Telephonic Post-Test Clinical Correlation with a DHA-Licensed Consultant Medical Geneticist.
- ✓ Direct Billing Verification: WhatsApp +971 54 548 8731 for instant insurance pre‑approval.
Test Overview & Methodology
The ADAM17 Gene Inflammatory Skin and Bowel Disease, Neonatal, Type 1 Genetic Test identifies pathogenic variants in the ADAM17 gene, enabling definitive molecular diagnosis of this ultra‑rare neonatal syndrome characterised by severe skin lesions and intractable diarrhoea. In the UAE, this test provides lifesaving clarity for families and clinicians, guiding personalised management and genetic counselling.
| Attribute | Our DHA‑Approved NGS Test | Closest Alternative (Targeted Single‑Exon Sequencing) |
|---|---|---|
| Precision | Full‑gene coverage with 100x mean depth, intronic flanking regions | Limited to pre‑selected hotspots; may miss novel or deep intronic mutations |
| Methodology | NGS (Next Generation Sequencing) + Sanger confirmation | Sanger sequencing of selected exons only |
| Turnaround Time | 3 to 4 Weeks (validated by ISO 9001:2015) | 6–8 Weeks, often delayed by batch processing |
| Clinical Utility | Directs targeted therapy (e.g., anti‑TNF‑α) and family planning | May provide incomplete genotype‑phenotype correlation |
| Regulatory Alignment | Fully compliant with UAE PDPL, Federal Law No. 2 of 2019, and DHA facility license 1143 | Variable compliance; often lacks mandatory paediatric consent protocols |
Physician Insight & Safety Protocols
“As a DHA‑licensed Consultant Medical Geneticist, I cannot overstate that a positive ADAM17 result must be correlated with the clinical phenotype—particularly the characteristic erythroderma and watery diarrhoea unresponsive to standard formula. This test confirms a monogenic aetiology, but multidisciplinary care involving neonatology, dermatology, and gastroenterology remains the cornerstone of treatment.”
— Lina Osama Zaki Quteineh (DHA: 9294403), Consultant Medical Genetics
Medication Warning
Do not discontinue prescribed medication without consulting your doctor. Genetic results inform—but do not replace—clinical judgment and therapeutic decisions.
Exclusion Criteria & Emergency Red Flags
- Phlebotomy Contraindications: Haemodynamic instability, uncorrected coagulopathy, or severe thrombocytopenia.
- Informed Consent: Legal guardian unable to provide valid consent for paediatric testing (in accordance with UAE Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Immediate Medical Attention Required If: The infant exhibits septic shock, extensive skin denudation with fluid loss, or acute intestinal perforation—these are not contraindications but require stabilisation before sample collection.
Patient FAQ & Clinical Guidance
1. Why is full ADAM17 gene sequencing recommended for my newborn with skin and bowel symptoms?
Snippet‑optimised answer: Full ADAM17 gene sequencing diagnoses neonatal inflammatory skin and bowel disease type 1, enabling early targeted therapies and informed family planning. Without this test, the condition may be misdiagnosed as severe eczema or infectious colitis, delaying life‑saving interventions such as tumour necrosis factor inhibitors. The test also clarifies inheritance patterns for future pregnancies.
2. How do I prepare my baby for the blood draw, and is home collection safe?
Snippet‑optimised answer: No fasting is needed; our ISO‑certified VIP paediatric phlebotomist uses a micro‑collection technique to minimise discomfort with just 0.5–1 mL of blood. Home collection adheres to cold‑chain standards and UAE PDPL data privacy; a DHA‑licensed nurse verifies consent and identity before the procedure. Mild bruising at the site may occur but resolves within a day.
3. Will insurance cover this ADAM17 test, and how do I claim?
Snippet‑optimised answer: Most UAE insurers reimburse medically indicated genetic tests with a DHA‑issued pre‑authorisation code; we verify coverage via WhatsApp at +971 54 548 8731 before collection. After billing, you receive an itemised invoice with ICD‑10 codes Q87.89, P83.8, and K90.8, which facilitates direct filing. Self‑pay patients can also use our 12‑month instalment plan.
UAE Regulatory & Data Privacy Adherence
This test is performed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, processed under DHA facility license 1143, and retained only with explicit consent. Patient confidentiality and data security are paramount.
Clinical & Logistical Metadata
| Test Name | ADAM17 Gene Inflammatory Skin and Bowel Disease, Neonatal, Type 1 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 weeks |
| Sample Type / Matrix | Peripheral whole blood (0.5–1 mL) |
| Methodology Used | NGS (Next Generation Sequencing) with Sanger confirmation |
| ICD-10-CM Code | Q87.89, P83.8, K90.8 |
| LOINC Code | 93025-5 |
| DHA Facility License & Laboratory Address | License No. 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians